PMID- 37167143
OWN - NLM
STAT- MEDLINE
DCOM- 20230515
LR  - 20230515
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 95
IP  - 3
DP  - 2023 Apr 26
TI  - [Interstitial pneumonia with autoimmune features: monocentric prospective study].
PG  - 224-229
LID - 10.26442/00403660.2023.03.202087 [doi]
AB  - AIM: To study demographic, clinical, serological and morphological features of 
      interstitial pneumonia with autoimmune features (IPAF), compare survival in IPAF 
      and interstitial lung disease in connective tissue diseases (CTD-ILD), and 
      identify predictors of mortality and transformation to CTD in the IPAF group. 
      MATERIALS AND METHODS: The IPAF group included 48 patients (75.0% women, median 
      age 57.5 years), CTD-ILD - 49 patients (79.6% women, median age 60.0 years). The 
      analysis of demographic, clinical, laboratory and instrumental data was 
      performed, as well as comparison of survival with the Kaplan-Meier method and the 
      log-rank test in the IPAF and CTD-ILD groups. In the IPAF group, predictors of 
      mortality and the development of CTD were studied with multivariate regression 
      analysis. RESULTS: Duration of observation period did not differ significantly in 
      the IPAF and CTD-ILD groups (40.0 and 37.0 months, respectively). Clinical 
      criteria of IPAF were observed in 25 (52.1%) patients, serological - in 44 
      (91.7%), morphological - in 44 (91.7%). Mortality in the IPAF group was 
      significantly higher than in the CTD-ILD group (29.2 and 6.1%, respectively; 
      p=0.023). The presence of diabetes mellitus, CT-pattern of usual interstitial 
      pneumonia, and an initial low forced vital capacity value were independent 
      predictors of mortality in the IPAF group. During the observation period, the 
      development of CTD was noted in 4 (8.3%) patients with IPAF. The independent 
      predictor of the CTD development was the increased C-reactive protein level. 
      CONCLUSION: IPAF is characterized by a lower survival rate compared to CTD-ILD, 
      and a relatively low risk of CTD transformation.
FAU - Akulkina, L A
AU  - Akulkina LA
AUID- ORCID: 0000-0002-4307-8882
AD  - Sechenov First Moscow State Medical University (Sechenov University).
FAU - Shchepalina, A A
AU  - Shchepalina AA
AUID- ORCID: 0000-0002-1826-0519
AD  - Sechenov First Moscow State Medical University (Sechenov University).
FAU - Moiseev, A S
AU  - Moiseev AS
AUID- ORCID: 0000-0002-5296-7622
AD  - Sechenov First Moscow State Medical University (Sechenov University).
AD  - Lomonosov Moscow State University.
FAU - Brovko, M Y
AU  - Brovko MY
AUID- ORCID: 0000-0003-0023-2701
AD  - Sechenov First Moscow State Medical University (Sechenov University).
FAU - Sholomova, V I
AU  - Sholomova VI
AUID- ORCID: 0000-0002-8785-7968
AD  - Sechenov First Moscow State Medical University (Sechenov University).
FAU - Moiseev, S V
AU  - Moiseev SV
AUID- ORCID: 0000-0002-7232-4640
AD  - Sechenov First Moscow State Medical University (Sechenov University).
AD  - Lomonosov Moscow State University.
LA  - rus
PT  - English Abstract
PT  - Journal Article
DEP - 20230426
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
SB  - IM
MH  - Humans
MH  - Female
MH  - Middle Aged
MH  - Male
MH  - Prospective Studies
MH  - *Lung Diseases, Interstitial/diagnosis/epidemiology/etiology
MH  - *Idiopathic Pulmonary Fibrosis
MH  - *Connective Tissue Diseases/complications/diagnosis/epidemiology
MH  - Vital Capacity
MH  - *Autoimmune Diseases/complications/diagnosis/epidemiology
MH  - Retrospective Studies
OTO - NOTNLM
OT  - connective tissue disease
OT  - interstitial lung disease
OT  - interstitial pneumonia with autoimmune features
EDAT- 2023/05/11 19:13
MHDA- 2023/05/15 06:42
CRDT- 2023/05/11 13:13
PHST- 2023/04/24 00:00 [received]
PHST- 2023/04/24 00:00 [accepted]
PHST- 2023/05/15 06:42 [medline]
PHST- 2023/05/11 19:13 [pubmed]
PHST- 2023/05/11 13:13 [entrez]
AID - 10.26442/00403660.2023.03.202087 [doi]
PST - epublish
SO  - Ter Arkh. 2023 Apr 26;95(3):224-229. doi: 10.26442/00403660.2023.03.202087.